GlassScriptPhysician profile
Shoaib Qureshi
NPI 1417056250
$1,975.73
in general payments reported to CMS, 2019-2025
30 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $480 · 2021: $578 · 2022: $217 · 2023: $38.10 · 2024: $78.09 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $484.34 | 2019-2023 | Wegovy |
| Sunovion Pharmaceuticals INC. | $235.48 | 2019-2020 | |
| Hologic Sales and Service, LLC | $170.87 | 2021-2022 | |
| Gilead Sciences, INC. | $165.39 | 2019-2021 | |
| Medtronic, INC. | $98.33 | 2021 | |
| Acorda Therapeutics, INC | $96.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $61.82 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.82 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $51.29 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $42.38 | 2019-2020 | |
| Amgen INC. | $40.95 | 2021-2024 | Tepezza |
| Pulmonx Corporation | $40.63 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Pfizer INC. | $38.72 | 2019-2021 | |
| Medtronic Minimed, INC. | $38.03 | 2019-2020 | |
| Indivior INC. | $37.93 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aegerion Pharmaceuticals, INC. | $37.91 | 2019 | |
| Abbott Laboratories | $34.63 | 2021 | |
| Lilly USA, LLC | $28.43 | 2020 | |
| Dexcom, INC. | $26.96 | 2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $23.45 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.02 | 2024 | |
| Inspire Medical Systems, INC. | $20.54 | 2025 | Inspire |
| Amarin Pharma, INC. | $17.97 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.56 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $16.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.40 | 2022 | |
| Abbvie INC. | $15.51 | 2021 | |
| Insulet Corporation | $15.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.30 | 2020 | |
| Hikma Pharmaceuticals USA | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoaib Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.